Matthew A Gubens1, Jody C Chuang2, Wallace Akerley3, Corey J Langer4, Christelle Clément-Duchêne5, Melanie San Pedro-Salcedo2, A Dimitrios Colevas2, Konstantin Dragnev6, Mark A Socinski7, Heather A Wakelee2. 1. Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA, USA. 2. Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA. 3. Department of Medicine, University of Utah, Salt Lake City, UT, USA. 4. Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 5. Department of Oncology, Institut de Cancérologie de Lorraine, Nancy, France. 6. Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. 7. Florida Hospital Cancer Institute, Orlando, FL, USA.
Abstract
BACKGROUND: Brain metastases are a common complication of advanced non-small cell lung cancer (NSCLC). Patients with brain metastases were excluded from the registration trials of bevacizumab that showed a survival benefit with the use of angiogenesis inhibition. METHODS: In this study, we pooled data from two separate trials designed to evaluate the risk of central nervous system (CNS) hemorrhage in patients with stable treated brain metastases to look specifically at both the safety and efficacy of bevacizumab and pemetrexed when used as second-line treatment in NSCLC patients with stable treated brain metastases. RESULTS: We report acceptable safety and promising efficacy from our analysis. CONCLUSIONS: Our study adds further evidence of safety of administering pemetrexed and bevacizumab to patients with stable brain metastases. There is increasing roles for systemic therapies to treat stable brain metastases for patients with advanced NSCLC.
BACKGROUND: Brain metastases are a common complication of advanced non-small cell lung cancer (NSCLC). Patients with brain metastases were excluded from the registration trials of bevacizumab that showed a survival benefit with the use of angiogenesis inhibition. METHODS: In this study, we pooled data from two separate trials designed to evaluate the risk of central nervous system (CNS) hemorrhage in patients with stable treated brain metastases to look specifically at both the safety and efficacy of bevacizumab and pemetrexed when used as second-line treatment in NSCLC patients with stable treated brain metastases. RESULTS: We report acceptable safety and promising efficacy from our analysis. CONCLUSIONS: Our study adds further evidence of safety of administering pemetrexed and bevacizumab to patients with stable brain metastases. There is increasing roles for systemic therapies to treat stable brain metastases for patients with advanced NSCLC.
Entities:
Keywords:
Brain metastases; bevacizumab; non-small cell lung cancer (NSCLC); pemetrexed
Authors: Daniel B Costa; Alice T Shaw; Sai-Hong I Ou; Benjamin J Solomon; Gregory J Riely; Myung-Ju Ahn; Caicun Zhou; S Martin Shreeve; Paulina Selaru; Anna Polli; Patrick Schnell; Keith D Wilner; Robin Wiltshire; D Ross Camidge; Lucio Crinò Journal: J Clin Oncol Date: 2015-01-26 Impact factor: 44.544
Authors: Mark A Socinski; Corey J Langer; Jane E Huang; Margaret M Kolb; Peter Compton; Lisa Wang; Wallace Akerley Journal: J Clin Oncol Date: 2009-09-08 Impact factor: 44.544
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger Journal: Lancet Oncol Date: 2016-06-03 Impact factor: 41.316
Authors: Mark E Linskey; David W Andrews; Anthony L Asher; Stuart H Burri; Douglas Kondziolka; Paula D Robinson; Mario Ammirati; Charles S Cobbs; Laurie E Gaspar; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Steven N Kalkanis Journal: J Neurooncol Date: 2009-12-04 Impact factor: 4.130
Authors: Helena A Yu; Luis G Paz-Ares; James Chih-Hsin Yang; Ki Hyeong Lee; Pilar Garrido; Keunchil Park; Joo-Hang Kim; Dae Ho Lee; Huzhang Mao; Sameera R Wijayawardana; Ling Gao; Rebecca R Hozak; Bo H Chao; David Planchard Journal: Clin Cancer Res Date: 2020-10-12 Impact factor: 12.531